- Home
- ABSI vs PRTC Comparison
ABSI vs PRTC Comparison
Compare ABSI & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- PRTC
- Stock Information
- Founded
- ABSI 2011
- PRTC 2015
- Country
- ABSI United States
- PRTC United States
- Employees
- ABSI N/A
- PRTC N/A
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- PRTC Biotechnology: Pharmaceutical Preparations
- Sector
- ABSI Health Care
- PRTC Health Care
- Exchange
- ABSI Nasdaq
- PRTC Nasdaq
- Market Cap
- ABSI 505.4M
- PRTC 435.0M
- IPO Year
- ABSI 2021
- PRTC N/A
- Fundamental
- Price
- ABSI $4.53
- PRTC $17.26
- Analyst Decision
- ABSI Strong Buy
- PRTC
- Analyst Count
- ABSI 6
- PRTC 0
- Target Price
- ABSI $7.98
- PRTC N/A
- AVG Volume (30 Days)
- ABSI 7.2M
- PRTC 2.2K
- Earning Date
- ABSI 11-11-2025
- PRTC 08-28-2025
- Dividend Yield
- ABSI N/A
- PRTC N/A
- EPS Growth
- ABSI N/A
- PRTC N/A
- EPS
- ABSI N/A
- PRTC 0.20
- Revenue
- ABSI $4,138,000.00
- PRTC $6,391,000.00
- Revenue This Year
- ABSI $32.44
- PRTC N/A
- Revenue Next Year
- ABSI $359.77
- PRTC N/A
- P/E Ratio
- ABSI N/A
- PRTC $8.46
- Revenue Growth
- ABSI 27.32
- PRTC 1265.60
- 52 Week Low
- ABSI $2.01
- PRTC $13.30
- 52 Week High
- ABSI $6.33
- PRTC $24.99
- Technical
- Relative Strength Index (RSI)
- ABSI 64.46
- PRTC 46.41
- Support Level
- ABSI $3.45
- PRTC $17.63
- Resistance Level
- ABSI $5.23
- PRTC $18.17
- Average True Range (ATR)
- ABSI 0.42
- PRTC 0.21
- MACD
- ABSI 0.12
- PRTC -0.07
- Stochastic Oscillator
- ABSI 67.50
- PRTC 15.66
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About PRTC PureTech Health plc
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.